| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8439248 | European Journal of Cancer | 2018 | 9 Pages |
Abstract
Prognosis of patients after developing BMs varies significantly according to the subtype. The outcome in this cohort is similarly poor as in triple-negative and HR-positive/HER2-negative patients. Our results underline the high medical need for improvement of treatment and prevention strategies for BMs in breast cancer patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
I. Witzel, E. Laakmann, R. Weide, T. Neunhöffer, T.-J. Park-Simon, M. Schmidt, P.A. Fasching, T. Hesse, A. Polasik, S. Mohrmann, F. Würschmidt, C. Schem, C. Bechtner, R. Würstlein, T. Fehm, V. Möbus, N. Burchardi, S. Loibl, V. Müller,